These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32444794)

  • 1. High-throughput functional evaluation of BRCA2 variants of unknown significance.
    Ikegami M; Kohsaka S; Ueno T; Momozawa Y; Inoue S; Tamura K; Shimomura A; Hosoya N; Kobayashi H; Tanaka S; Mano H
    Nat Commun; 2020 May; 11(1):2573. PubMed ID: 32444794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
    Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
    Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.
    Richardson ME; Hu C; Lee KY; LaDuca H; Fulk K; Durda KM; Deckman AM; Goldgar DE; Monteiro ANA; Gnanaolivu R; Hart SN; Polley EC; Chao E; Pesaran T; Couch FJ
    Am J Hum Genet; 2021 Mar; 108(3):458-468. PubMed ID: 33609447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
    Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
    Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
    Guidugli L; Shimelis H; Masica DL; Pankratz VS; Lipton GB; Singh N; Hu C; Monteiro ANA; Lindor NM; Goldgar DE; Karchin R; Iversen ES; Couch FJ
    Am J Hum Genet; 2018 Feb; 102(2):233-248. PubMed ID: 29394989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain.
    Hu C; Huang H; Na J; Lumby C; Abozaid M; Holdren MA; Rao TJ; Karam R; Pesaran T; Weyandt JD; Csuy CM; Seelaus CA; Young CC; Fulk K; Heidari Z; Morais Lyra PC; Couch RE; Persons B; Polley EC; Gnanaolivu RD; Boddicker NJ; Monteiro ANA; Yadav S; Domchek SM; Richardson ME; Couch FJ
    Am J Hum Genet; 2024 Mar; 111(3):584-593. PubMed ID: 38417439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
    Gornstein EL; Sandefur S; Chung JH; Gay LM; Holmes O; Erlich RL; Soman S; Martin LK; Rose AV; Stephens PJ; Ross JS; Miller VA; Ali SM; Blau S
    Clin Breast Cancer; 2018 Apr; 18(2):184-188. PubMed ID: 29325860
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional assays for analysis of variants of uncertain significance in BRCA2.
    Guidugli L; Carreira A; Caputo SM; Ehlen A; Galli A; Monteiro AN; Neuhausen SL; Hansen TV; Couch FJ; Vreeswijk MP;
    Hum Mutat; 2014 Feb; 35(2):151-64. PubMed ID: 24323938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants.
    Sahu S; Sullivan TL; Mitrophanov AY; Galloux M; Nousome D; Southon E; Caylor D; Mishra AP; Evans CN; Clapp ME; Burkett S; Malys T; Chari R; Biswas K; Sharan SK
    PLoS Genet; 2023 Sep; 19(9):e1010940. PubMed ID: 37713444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The functional impact of variants of uncertain significance in BRCA2.
    Mesman RLS; Calléja FMGR; Hendriks G; Morolli B; Misovic B; Devilee P; van Asperen CJ; Vrieling H; Vreeswijk MPG
    Genet Med; 2019 Feb; 21(2):293-302. PubMed ID: 29988080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors plough on.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356598
    [No Abstract]   [Full Text] [Related]  

  • 14. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
    Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
    Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
    Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
    Guidugli L; Pankratz VS; Singh N; Thompson J; Erding CA; Engel C; Schmutzler R; Domchek S; Nathanson K; Radice P; Singer C; Tonin PN; Lindor NM; Goldgar DE; Couch FJ
    Cancer Res; 2013 Jan; 73(1):265-75. PubMed ID: 23108138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
    [No Abstract]   [Full Text] [Related]  

  • 19. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
    Toland AE; Andreassen PR
    J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
    Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.